AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.65, $0.05 worse than the analyst estimate of $2.70. Revenue for the quarter came in at $14.46 billion versus the consensus estimate of $14.02 billion.

GUIDANCE:

AbbVie sees FY2024 EPS of $10.71-$10.91, versus the consensus of $10.90.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Rubio to visit Gulf states amid Iran deal concerns
• AeroVironment restates quarterly financials, citing $89M goodwill error